The honest verdict

Semaglutide works. That's not the controversy. The controversy is who it's reasonable for, what it costs to stay on it for life, and whether the lifestyle change you should be making first is being skipped because the injection is faster.

For someone with type 2 diabetes and obesity, GLP-1 agonists are arguably the most important class of drugs introduced in metabolic medicine in twenty years. The cardiovascular outcome data (SUSTAIN-6, SELECT) showed reduced rates of heart attack and stroke. The weight-loss data is the cleanest in the class. For that population, a clinician-supervised semaglutide protocol stacked with diet and movement is a defensible choice.

For someone whose BMI is 26, who has not tried the basics — a calorie deficit, 8,000 daily steps, two strength sessions a week, seven hours of sleep — semaglutide is being marketed as the easy option. It isn't. It's a weekly injection with a side-effect profile, a price tag of roughly $1,000 to $1,300 per month at retail, and a regain pattern when you stop. Stop is the word the marketing skips.

"I have tried it. It's not what got me here. The diet change is what got me here." — Lizzo, on the Just Trish podcast, June 2025, on whether she has used Ozempic.

That quote is the cleanest celebrity statement in the entire conversation. She tried it, she stopped, she credits the food. The honest version of GLP-1 use looks more like that than the version selling it.

How semaglutide actually works

Semaglutide is a GLP-1 receptor agonist. Glucagon-like peptide 1 (GLP-1) is a natural hormone the gut releases after eating. It does three things: it tells the pancreas to release insulin (which is why it works for type 2 diabetes), it slows gastric emptying (which is why food sits in your stomach longer and you feel fuller), and it acts on appetite-regulating neurons in the brain, especially the hypothalamus and brainstem (which is why "food noise" — the constant background hum of wanting to eat — gets quieter).

The body's own GLP-1 has a half-life measured in minutes. Pharmaceutical semaglutide has a half-life of about a week, which is why dosing is once-weekly. The drug doesn't burn fat. It changes the appetite signal. People eat less because they want less. The calorie deficit does the actual weight loss.

What the trials showed

• STEP-1 (NEJM, 2021) — 1,961 adults with obesity, 68 weeks of 2.4 mg weekly semaglutide. Mean body-weight reduction: 14.9% vs 2.4% placebo. Roughly 86% of participants lost at least 5% of body weight; 50% lost at least 15%.
• STEP-3 (JAMA, 2021) — Semaglutide plus intensive behavioral therapy: 16% mean weight loss vs 5.7% placebo plus same therapy.
• STEP-4 (JAMA, 2022) — Participants randomized to continue semaglutide kept losing weight to 7.9% additional reduction. Those who switched to placebo at week 20 regained 6.9% of body weight.
• SELECT (NEJM, 2023) — In adults with overweight/obesity and established cardiovascular disease (no diabetes), semaglutide reduced cardiovascular events by 20%.

These are the numbers. They are good numbers. They are also numbers from a trial population — supported, monitored, on the medication consistently. Real-world adherence is messier. A 2024 Obesity analysis from a US health-claims database found roughly two-thirds of people prescribed a GLP-1 for weight loss had stopped within a year.

Who's actually tried it (and who hasn't)

Real Easy Diet's celebrity desk reports what celebrities have publicly confirmed about Ozempic — not tabloid speculation. The honest list is shorter than the gossip would suggest.

Confirmed: Lizzo tried it and stopped

On the Just Trish podcast in June 2025, Lizzo confirmed she tried Ozempic and explicitly said the diet change — moving off a vegan diet, eating whole-food protein, training five days a week — was what produced her weight change, not the injection. That's a celebrity stating the medication didn't carry the result.

Confirmed: Amy Schumer tried it and quit

Amy Schumer has spoken publicly about trying Ozempic and discontinuing because of side effects — particularly the gastrointestinal ones. Her separate body changes are linked to a Cushing syndrome diagnosis and an endometriosis surgery, not to the medication. Tabloids that frame her as "an Ozempic story" are wrong twice.

Important context: Selena Gomez and lupus medication

Selena Gomez's body-weight fluctuations are explicitly not an Ozempic story. She has spoken openly about taking lupus medication that causes water retention, and her own quote — "When I'm on it, I hold a lot of water weight" — is the cleanest source. Confusing autoimmune-medication side effects with weight-loss medication side effects is a category error this site refuses to make.

Explicitly denied: Kelly Clarkson

Kelly Clarkson has said publicly that she takes a non-Ozempic medication that "helps break down sugar." She has explicitly distinguished this from semaglutide. Her routine includes the medication, walking, and a Texas-style protein-led eating pattern her doctor recommended.

Explicitly denied: Kelly Osbourne

Kelly Osbourne has explicitly denied using Ozempic, attributing her 85-pound loss to gastric sleeve surgery and a low-carb, low-sugar diet after a high-risk pregnancy. The denial is on the record.

What to expect, week by week

These ranges are pulled from the published trial data and from clinician-reported real-world dosing. Individual experience varies — that's what dose-titration protocols are for.

• Week 1 to 4 (titration): Starting dose is 0.25 mg weekly, escalating monthly. Side effects peak. Nausea, sometimes vomiting, constipation, fatigue. Most people lose 1 to 4 pounds in the first month, mostly from reduced food intake driven by the slowed gastric emptying. The "food noise" begins to quiet.
• Week 4 to 12: Dose climbs to 1.0 mg or 1.7 mg. Weight loss steepens — 1 to 2 pounds per week is common at this stage. GI side effects begin to ease for most people. Cravings are reported as much weaker. Energy can be lower than baseline because intake is lower than baseline.
• Week 12 to 26: Most people reach target dose (2.4 mg for Wegovy) and are settling into the curve. Cumulative loss often hits 8 to 12% of body weight. Strength and stamina depend heavily on whether the person is exercising and eating enough protein. Muscle loss risk is highest here.
• Week 26 to 68: Trial-mean total loss reaches 14.9%. Plateau is usually around month 12 to 15. The medication is now a maintenance tool. Stopping at this stage is what the regain studies measured.
• Stopping: Two-thirds regain within 12 months unless the lifestyle changes that supported the loss are durable. Cravings return as gastric emptying normalizes.

Risks and side effects, honestly

The full FDA prescribing label is a more honest document than most marketing pages. The major categories:

Common (≥5%)

• Nausea — 44% in STEP-1
• Diarrhea — 30%
• Vomiting — 24%
• Constipation — 24%
• Abdominal pain — 20%
• Fatigue, headache, dyspepsia, eructation

Less common but serious

• Pancreatitis — Rare but documented. Severe abdominal pain that radiates to the back is a stop-and-call-your-doctor signal.
• Gallbladder disease — Cholecystitis and gallstones are elevated, especially during rapid weight loss.
• Acute kidney injury — Linked to dehydration from persistent vomiting or diarrhea.
• Hypoglycemia — Mainly when stacked with insulin or sulfonylureas.
• Diabetic retinopathy worsening — Reported in patients with prior history.

Black-box warning

Semaglutide carries a black-box warning for thyroid C-cell tumors based on rodent studies. Whether the rodent finding translates to humans is not established, but the contraindication is firm: anyone with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2, must not take it.

Muscle loss and "Ozempic face"

Rapid weight loss reduces fat under the skin of the face — that's the "Ozempic face" the press named. The bigger metabolic concern is total lean-mass loss. A 2024 Lancet sub-analysis found up to 40% of weight lost on semaglutide can come from lean tissue when no resistance training is added. Strength work and high-protein eating during a GLP-1 protocol is non-negotiable for long-term metabolic health.

If you're going to do it, stack it with

Semaglutide alone is not a complete weight-management plan. Anyone running a GLP-1 protocol should pair it with the basics it bypasses:

• A measured calorie target. Use our calorie deficit calculator to set a sustainable daily intake. The medication will make you naturally eat less; understand the floor.
• A protein floor. 0.7 to 1.0 g per pound of bodyweight. Our 7-day meal plan lays out how to hit the number without inventing a hobby.
• Resistance training. Two to three sessions per week, full-body. The Lancet sub-analysis above is the reason this is non-negotiable, not optional.
• Daily walking. 7,000 to 10,000 steps. See how many steps a day for the dose-response curve.
• Hydration. Persistent vomiting or diarrhea can dehydrate fast. Water targets matter more on this medication, not less.
• Sleep. Sleep debt undermines GLP-1 weight loss the same way it undermines any weight loss.
• Body-composition tracking. Don't just weigh yourself. Track waist circumference and grip strength as a proxy for muscle. BMI is the noisiest measure for weight-loss tracking — use it as a starting reference, not a target.

Better-evidenced alternatives (or first steps)

For someone whose BMI is borderline or who hasn't yet built the basics, these methods have decades of cleaner safety data and many of the same metabolic benefits at lower cost and lower risk:

• The Mediterranean diet — Cleanest cardiovascular evidence in human history, sustainable, low cost. PREDIMED reanalysis showed 30% reduction in cardiovascular events.
• A walking program — 8,000+ daily steps stacked with calorie control produces the same cardiovascular and metabolic gains for most adults at zero cost.
• Intermittent fasting — 3 to 8% body-weight loss in trials. Not for everyone, but no medication, no injection.
• Pilates and yoga — Not the calorie burner, but a real muscle-preservation, posture, and stress tool that compounds when stacked with diet.

For someone with diabetes, established cardiovascular disease, or a BMI well into the 30s where lifestyle alone hasn't moved the dial: a clinician-supervised GLP-1 protocol is a real medical option. Talk to a doctor. Don't ask the internet.

Telehealth referral, named and disclosed

Telehealth platforms like Ro and Hims & Hers prescribe semaglutide and compounded GLP-1s where state law and FDA supply rules allow. Real Easy Diet does not currently have an active affiliate relationship with any GLP-1 telehealth platform. We name them because readers ask, and because the alternative is pretending the option doesn't exist.

Before you click anything: verify the prescriber is licensed in your state, ask whether the medication is brand-name FDA-approved or compounded (compounded GLP-1s carry separate FDA warnings), and ask what monitoring is included. The cheapest GLP-1 prescription is rarely the safest one.

FAQ

Read more on Real Easy Diet

• Lizzo: tried Ozempic, said the diet change is what worked
• Amy Schumer on Ozempic side effects (and Cushing syndrome)
• Selena Gomez and lupus medication — not Ozempic
• Kelly Clarkson: a non-Ozempic medication, walking, protein
• Kelly Osbourne: surgery, not Ozempic — in her words
• The Mediterranean diet — the cleanest evidence in the field
• Intermittent fasting: 3 to 8% body-weight loss, no injection
• Walking for weight loss — the dose-response curve
• Calorie deficit calculator
• BMI calculator (and why BMI alone is the wrong target)
• 7-day meal plan to hit your protein floor
• How many steps a day to lose weight
• How much water on a GLP-1 protocol
• Semaglutide vs tirzepatide — full drug comparison
• Tirzepatide vs retatrutide — the triple-agonist race
• GLP-1 natural alternatives — what the research shows
• GLP-1 side effects management
• The GLP-1 off-ramp — sustainable loss after stopping

Sources

• Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1), NEJM 2021
• Wadden TA et al. — Semaglutide plus Intensive Behavioral Therapy (STEP-3), JAMA 2021
• Rubino D et al. — Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP-4), JAMA 2022
• Lincoff AM et al. — Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT), NEJM 2023
• FDA — Medications Containing Semaglutide
• Mayo Clinic — Semaglutide drug information
• Wilding JPH et al. — STEP-4 extension, regain after discontinuation